Abstract
A phage-displayed peptide CGNSNPKSC (GX1) was obtained previously in our lab, which could specifically bind to the vasculature of human gastric cancer. GX1-rmhTNFα was a fusion protein of GX1 and recombinant mutant human tumor necrosis factor α (rmhTNFα), which was designed by us with the expectation of enhancing selectivity of rmhTNFα. The DNA fragment encoding GX1 was cloned into the vector pBV220 with rmhTNFα between the EcoRI site and the BamHI site, and then expressed in Escherichia coli DH5α by temperature induction. Subsequently, E. coli DH5α was lysed, and the GX1-rmhTNFα protein was found in both soluble form and inclusion bodies. The protein was fractionated with ammonium sulfate deposition from 30% to 60%, and purified by cation and anion exchange chromatography using SP Sepharose Fast Flow column and Q Sepharose Fast Flow column. The purity of protein was then identified by SDS-PAGE and HPLC. Subsequent studies showed that GX1-rmhTNFα had high bioactivity of 5.65 × 108 IU/ml, which was similar with natural human TNFα and could reach the tumor site relatively faster than rmhTNFα.




Similar content being viewed by others
Abbreviations
- HPLC:
-
High performance liquid chromatography
- FMMU:
-
The fourth military medical university
- ELISA:
-
Enzyme-linked immunosorbent assay
- PBST:
-
Phosphate buffer solution tween-20
- HRP:
-
Horse radish peroxidase
- SPECT:
-
Single photon emission computed tomography
References
Folkman, J. (2003). Angiogenesis and apoptosis. Seminars in Cancer Biology, 13, 159–167. doi:10.1016/S1044-579X(02)00133-5.
Pastorino, F., Paolo, D., Di Piccardi, F., Nico, B., Ribatti, D., Daga, A., et al. (2008). Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal Doxorubicin. Clinical Cancer Research, 14, 7320–7329. doi:10.1158/1078-0432.CCR-08-0804.
Norden, A. D., Drappatz, J., & Wen, P. Y. (2008). Novel anti-angiogenic therapies for malignant gliomas. The Lancet Neurology, 7, 1152–1160. doi:10.1016/S1474-4422(08)70260-6.
Kamba, T., & McDonald, D. M. (2007). Mechanisms of adverse effects of anti-VEGF therapy for cancer. British Journal of Cancer, 96, 1788–1795. doi:10.1038/sj.bjc.6603813.
Zhi, M., Wu, K. C., Dong, L., Hao, Z. M., Deng, T. Z., Hong, L., et al. (2004). Characterization of a specific phage-displayed peptide binding to vasculature of human gastric cancer. Cancer Biology & Therapy, 3, 1232–1235.
Hui, X. L., Han, Y., Liang, S. H., Liu, Z. G., Liu, J., Hong, L., et al. (2008). Specific targeting of the vasculature of gastric cancer by a new tumor-homing peptide CGNSNPKSC. Journal of Controlled Release, 131, 86–93. doi:10.1016/j.jconrel.2008.07.024.
Old, L. J. (1985). Tumor necrosis factor (TNF). Science, 230, 630–632. doi:10.1126/science.2413547.
Fajardo, L. F., Kwan, H. H., Kowalski, J., Prionas, S. D., & Allison, A. C. (1992). Dual role of tumor necrosis factor-alpha in angiogenesis. American Journal of Pathology, 140, 539–544.
Renard, N., Lienard, D., Lespagnard, L., Eggermont, A., Heimann, R., & Lejeune, F. (1994). Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high dose tumor necrosis factor alpha (rTNF alpha). International Journal of Cancer, 57, 656–663. doi:10.1002/ijc.2910570508.
Mortara, L., Balza, E., Sassi, F., Castellani, P., Carnemolla, B., De Lerma Barbaro, A., et al. (2007). Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan. European Journal of Immunology, 37, 3381–3392. doi:10.1002/eji.200737450.
Baumgarten, A. J., Fiebig, H. H., & Burger, A. M. (2007). Molecular analysis of xenograft models of human cancer cachexia—possibilities for therapeutic intervention. Cancer Genomics & Proteomics, 4, 223–231.
Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N., & Lejeune, F. J. (1992). High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. Journal of Clinical Oncology, 10, 52–60.
Cooke, S. P., Pedley, R. B., Boden, R., Begent, R. H., & Chester, K. A. (2002). In vivo tumor delivery of a recombinant single chain fv: tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein. Bioconjugate Chemistry, 13, 7–15. doi:10.1021/bc000178a.
Van der Veen, A. H., Eggermont, A. M., Seynhaeve, A. L., van Tiel, S. T., & ten Hagen, T. L. (1998). Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats. International Journal of Cancer, 77, 901–906.
Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., & Corti, A. (2000). Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nature Biotechnology, 18, 1185–1190. doi:10.1038/81183.
Menard, L. C., Minns, L. A., Darche, S., Mielcarz, D. W., Foureau, D. M., Roos, D., et al. (2007). B cells amplify IFN-gamma production by T cells via a TNF-alpha-mediated mechanism. Journal of Immunology (Baltimore, MD.: 1950), 179, 4857–4866.
Sun, M., & Fink, P. J. (2007). A new class of reverse signaling costimulators belongs to the TNF family. Journal of Immunology (Baltimore, MD.: 1950), 179, 4307–4312.
Zheng, L., Yang, Y., Guocai, L., Pauza, C. D., & Salvato, M. S. (2007). HIV Tat protein increases Bcl-2 expression in monocytes which inhibits monocyte apoptosis induced by tumor necrosis factor-alpha-related apoptosis-induced ligand. Intervirology, 50, 224–228. doi:10.1159/000100565.
Kanbur, N., Mesci, L., Derman, O., Turul, T., Cuhadaroğlu, F., Kutluk, T., et al. (2008). Tumor necrosis factor alpha-308 gene polymorphism in patients with anorexia nervosa. The Turkish Journal of Pediatrics, 50, 219–222.
Han, W., Zhang, Y., Yan, Z., & Shi, J. (2003). Construction of a new tumour necrosis factor fusion-protein expression vector for high-level expression of heterologous genes in Escherichia coli. Biotechnology and Applied Biochemistry, 37, 109–113. doi:10.1042/BA20020070.
Wang, H., Yan, Z., Shi, J., Han, W., & Zhang, Y. (2006). Expression, purification, and characterization of a neovasculature targeted rmhTNF-alpha in Escherichia coli. Protein Expression and Purification, 45, 60–65. doi:10.1016/j.pep.2005.05.009.
Yang, F., Gu, N., Chen, D., Xi, X., Zhang, D., Li, Y., et al. (2008). Experimental study on cell self-sealing during sonoporation. Journal of Controlled Release, 131, 205–210. doi:10.1016/j.jconrel.2008.07.038.
Boulanger, P. (2009). Purification of bacteriophages and SDS-PAGE analysis of phage structural proteins from ghost particles. Methods in Molecular Biology (Clifton, N.J.), 502, 227–238.
Gilbert, J. S., Gilbert, S. A., Arany, M., & Granger, J. P. (2009). Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension, 53, 399–403. doi:10.1161/HYPERTENSIONAHA.108.123513.
Acknowledgments
We thank Yingqi Zhang (Professor, Biotechnology Center of FMMU, China) for the new recombinant human TNFα. This study was supported by the National High-Tech Project of China 2006AA02Z103, 2006AA02A402; the Key Project of PLA 06G087; the National Key Project of Basic Research 2004CB518702.
Author information
Authors and Affiliations
Corresponding author
Additional information
Shanshan Cao and Yan Liu contribute equally to this manuscript.
Rights and permissions
About this article
Cite this article
Cao, S., Liu, Y., Li, X. et al. Expression, Purification, and Characterization of Recombinant Protein GX1-rmhTNFα. Mol Biotechnol 43, 1–7 (2009). https://doi.org/10.1007/s12033-009-9170-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12033-009-9170-z


